Analysts are expecting Moderna to report revenue of $880 million in the third quarter, according to FactSet. The consensus ...

CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company’s investigational ...

Moderna’s market value has fallen by more than 90% — $185 billion, or a full Sony — from its 2021 peak to around $10 billion ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6.9% in the afternoon session after ongoing ...

Small study looks only at a cardiac biomarker; findings are in line with reduced myocarditis risk in mRNA COVID vaccines ...

Moderna (MRNA) just began dosing patients in a Phase 1/2 study of mRNA-2808, its experimental T-cell therapy for advanced multiple myeloma. This effort highlights Moderna's growing emphasis on cancer ...

Moderna stock is trading sharply lower Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.

Moderna Inc became the second U.S company to release data from a large study of its experimental vaccine, saying it was 94.5% effective against COVID-19.

Moderna's shares have been southbound for the past few years due to unimpressive financial results. However, progress with the pipeline could significantly boost the stock over the next five years.

Moderna beat analysts’ revenue expectations by 10.7% last quarter, reporting revenues of $142 million, down 41.1% year on ...

A shot analysts projected as a multibillion-dollar seller produced results “well below” the company’s expectations, ...

"Now we are an oncology company," Moderna CEO Stéphane Bancel told Insider.